Supernus Pharmaceuticals (SUPN) Announces Issuance of Two Patents Covering Trokendi XR
11/5/2012 9:24:34 AM
ROCKVILLE, Md., Nov. 5, 2012 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq:SUPN), a specialty pharmaceutical company, today announced the issuance of two patents (8,298,576 and 8,298,580) by the US Patent and Trademark Office (USPTO) covering Trokendi XR™, its novel once-daily extended-release topiramate product. Both patents were issued by the USPTO on October 30, 2012.
comments powered by